by Thibaut | Jun 13, 2021 | Banner in oneMedesis is a clinical development stage biopharmaceutical company that is engaged in the development of orally administered molecule drug candidates to address major unmet medical needs.
by Gilles Petitot | Mar 30, 2020 | Banner in one
by Thibaut | Jun 13, 2017 | Banner in oneAONYS® allows the administration of low doses of water-soluble pharmaceutical active ingredients. The final product is deposited on the mucosa of the mouth and delivered directly into the cells of the whole body
by Thibaut | Jun 13, 2017 | Banner in oneNP03 is a disease-modifying nano dose formulation of lithium citrate in an AONYS® reverse microemulsion. NP03 allows the delivery of lithium citrate to all tissues with a strong therapeutic efficacy at low doses.
by Thibaut | Jun 13, 2017 | Banner in onePreclinical studies on the disease-modifying effect of NP03 in AD have been conducted in McGill University, Montreal CA. NP03 is a disease modifying drug and induced neurogenesis. A phase II is planned for the treatment of psychosis associated with AD.
by Thibaut | Jun 13, 2017 | Banner in oneAfter a civil or military nuclear accident, there are no suitable decorporation treatments for large contaminated populations and no approved drug to be used after irradiation and free of serious side effects.